Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escherichia coli strain Nissle 1917 suspension vs vancomycin for Clostridium difficile associated diarrhoea
2017-004531-36Phase 2Terminated
- Sponsor
- Ardeypharm
- Start
- Jan 2018
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of escherichia coli nissle 1917 in Clostridioides difficile colitis (CDI) (2 arms), sponsored by Ardeypharm. Primary endpoint: CDAD healing rate at 14 days. Started Jan 2018; status: terminated.
02
Drugs
escherichia coli nissle 1917
03
Conditions
Clostridioides difficile colitis (CDI)
Beyond the preview
Go deeper on 2017-004531-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004531-36.